

# The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice.

Melissa Bou-Jaoudeh,<sup>1</sup> Sandrine Delignat,<sup>1</sup> Victoria Daventure,<sup>1</sup> Jan Astermark,<sup>2</sup> Hervé Lévesque,<sup>3</sup> Jordan D Dimitrov,<sup>1</sup> Claire Deligne,<sup>1</sup> Valérie Proulle<sup>1,4</sup> and Sébastien Lacroix-Desmazes<sup>1</sup>

<sup>1</sup>Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, CNRS, Sorbonne Université, Université Paris Cité, Paris, France; <sup>2</sup>Department for Translational Medicine, Skane University Hospital, Lund University, Malmö, Sweden; <sup>3</sup>Service de Médecine Interne, Normandie Université, UNIROUEN, Rouen, France and <sup>4</sup>Service d'Hématologie Biologique et Unité Fonctionnelle d'Hémostase, Hôpital Cochin, AP-HP Centre, Université Paris Cité, Paris, France

**Correspondence:** S. Lacroix-Desmazes  
[sebastien.lacroix-desmazes@inserm.fr](mailto:sebastien.lacroix-desmazes@inserm.fr)  
V. Proulle  
[Valerie.proulle@aphp.fr](mailto:Valerie.proulle@aphp.fr)

**Received:** August 5, 2022.  
**Accepted:** January 11, 2023.  
**Early view:** January 19, 2023.

<https://doi.org/10.3324/haematol.2022.281895>


©2023 Ferrata Storti Foundation

Published under a CC BY-NC license



## Supplemental data


Supplemental Figure S1



**Figure S1: Cleavage of human monoclonal anti-FVIII IgG by IdeS.** Binding of BOIIB2 (panels A and B), LE2E9 (panels C and D), and KM41 (panels E and F) IgG to FVIII following cleavage by IdeS. IgG1<sub>k</sub> (panels A, C, and E) and IgG4<sub>k</sub> (panels B, D, and F) at 1.66 μM were

incubated alone or with IdeS (0.14  $\mu\text{M}$ ) for 24 hr at 37°C. The binding of IgG (main graphs) and F(ab')<sub>2</sub> fragments (insets) to FVIII was validated by ELISA. Results are expressed in arbitrary units (AU, representative of 2 experiments) from optical density measured at 492 nm.

Supplemental Figure S2



**Figure S2. IdeS-mediated elimination of a pool of monoclonal anti-FVIII IgG in inhibitor-positive HA mice. Panel A.** HA mice (n=4 per group) were passively immunized with a pool of monoclonal IgG<sub>1k</sub> (BOIIB2, KM41, LE2E9, and BO2C11 at equimolar amounts of 3.4 µg for a total of 2800 BU/kg to reach 15±3 BU/mL after 24 hr, and injected twice with IdeS (0.6 mg/kg or 0.29 µM) or PBS 24 hr and 48 hr later. **Panels B, C and D.** The levels of intact IgG and/or sIgG (panel B, IgG concentration at 24 hr: 31.5±1.1 nM), the levels of F(ab')<sub>2</sub> fragments (panel C) and the inhibitory titers (panel D) were determined over time by ELISA and Bethesda assay (mean±SD). The dotted lines represent the respective detection thresholds: 0.03 µg/mL, 0.08 µg/mL and 0.6 BU/mL. The grey zone in panel D depicts inhibitory titers below 5 BU/ml, a titer that is compatible with the hemostatic efficacy of exogenous FVIII.